Literature DB >> 15047233

Arachidonyl ethanolamide induces apoptosis of uterine cervix cancer cells via aberrantly expressed vanilloid receptor-1.

Emmanuel Contassot1, Mirna Tenan, Valérie Schnüriger, Marie-Françoise Pelte, Pierre-Yves Dietrich.   

Abstract

OBJECTIVES: Delta(9)-Tetrahydrocannabinol, the active agent of Cannabis sativa, exhibits well-documented antitumor properties, but little is known about the possible effects mediated by endogenous cannabinoids on human tumors. In the present study, we analyzed the effect of arachidonyl ethanolamide (AEA) on cervical carcinoma (CxCa) cell lines.
METHODS: To assess the sensitivity of CxCa cells to AEA, we selected three cell lines that were exposed to increasing doses of AEA with or without antagonists to receptors to AEA. DNA fragmentation and caspase-7 activity were used as apoptosis markers. The expression of receptors to AEA were analyzed in CxCa cell lines as well as CxCa biopsies.
RESULTS: The major finding was that AEA induced apoptosis of CxCa cell lines via aberrantly expressed vanilloid receptor-1, whereas AEA binding to the classical CB1 and CB2 cannabinoid receptors mediated a protective effect. Furthermore, unexpectedly, a strong expression of the three forms of AEA receptors was observed in ex vivo CxCa biopsies.
CONCLUSIONS: Overall, these data suggest that the specific targeting of VR1 by endogenous cannabinoids or synthetic molecules offers attractive opportunities for the development of novel potent anticancer drugs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15047233     DOI: 10.1016/j.ygyno.2003.12.040

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  29 in total

1.  Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms.

Authors:  Luciano De Petrocellis; Alessia Ligresti; Aniello Schiano Moriello; Mariagrazia Iappelli; Roberta Verde; Colin G Stott; Luigia Cristino; Pierangelo Orlando; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

Review 2.  Endocannabinoids and immune regulation.

Authors:  Rupal Pandey; Khalida Mousawy; Mitzi Nagarkatti; Prakash Nagarkatti
Journal:  Pharmacol Res       Date:  2009-04-07       Impact factor: 7.658

3.  Physiology and pharmacology of the vanilloid receptor.

Authors:  Angel Messeguer; Rosa Planells-Cases; Antonio Ferrer-Montiel
Journal:  Curr Neuropharmacol       Date:  2006-01       Impact factor: 7.363

4.  Biophysical and biomechanical properties of neural progenitor cells as indicators of developmental neurotoxicity.

Authors:  Gautam Mahajan; Moo-Yeal Lee; Chandrasekhar Kothapalli
Journal:  Arch Toxicol       Date:  2019-08-19       Impact factor: 5.153

Review 5.  Cannabinoids, endocannabinoids, and cancer.

Authors:  Daniel J Hermanson; Lawrence J Marnett
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

Review 6.  Small molecule vanilloid TRPV1 receptor antagonists approaching drug status: can they live up to the expectations?

Authors:  Arpad Szallasi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-06-14       Impact factor: 3.000

7.  The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2.

Authors:  H A Patsos; D J Hicks; R R H Dobson; A Greenhough; N Woodman; J D Lane; A C Williams; C Paraskeva
Journal:  Gut       Date:  2005-08-11       Impact factor: 23.059

Review 8.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

9.  Cannabinoid-induced cell death in endometrial cancer cells: involvement of TRPV1 receptors in apoptosis.

Authors:  B M Fonseca; G Correia-da-Silva; N A Teixeira
Journal:  J Physiol Biochem       Date:  2018-02-13       Impact factor: 4.158

Review 10.  Changes in the endocannabinoid system may give insight into new and effective treatments for cancer.

Authors:  Gianfranco Alpini; Sharon Demorrow
Journal:  Vitam Horm       Date:  2009       Impact factor: 3.421

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.